e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Interstitial lung diseases II
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice
Nikolas Manitsopoulos (Athens, Greece), Nikolaos Manitsopoulos, Anastasia Kotanidou, Christina Magkou, Ioanna Ninou, Xia Tian, Vassilis Aidinis, Ralph Schermuly, Stylianos Orfanos
Source:
International Congress 2015 – Interstitial lung diseases II
Session:
Interstitial lung diseases II
Session type:
Thematic Poster Session
Number:
3837
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Nikolas Manitsopoulos (Athens, Greece), Nikolaos Manitsopoulos, Anastasia Kotanidou, Christina Magkou, Ioanna Ninou, Xia Tian, Vassilis Aidinis, Ralph Schermuly, Stylianos Orfanos. Treprostinil administration attenuates bleomycin-induced lung fibrosis in mice. Eur Respir J 2015; 46: Suppl. 59, 3837
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013
Selective endothelin-A receptor blockade attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
New approach to the treatment of bleomycin-induced lung fibrosis using pulmonary surfactant as pirfenidone carrier into the lung
Source: International Congress 2015 – Inflammation and remodelling in lung disease
Year: 2015
Sulforaphane attenuates lung fibrosis in bleomycin-induced pulmonary fibrosis via inhibition of TGF-beta/Smad signaling
Source: International Congress 2014 – ILDs 4
Year: 2014
Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
Novel biomarkers in bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease II
Year: 2013
Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
17(R)-resolvinD1 improves MMP-9/TIMP-1 imbalance leading to amelioration of pulmonary fibrosis in mice
Source: International Congress 2016 – ILD pathogenesis
Year: 2016
Effect of intratracheal administration of adipose-derived stromal cells on bleomycin-induced lung injury in a rat model
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015
Olodaterol attenuates bleomycin induced lung fibrosis in mice
Source: International Congress 2016 – Airway pharmacology: drug targets and mode of action
Year: 2016
Role of dendritic cells in pulmonary fibrosis in mice
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Interdependence of HIF1alpha /TGFbeta1 activity in induction of pulmonary fibrosis
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013
Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
Increased levels of oxidative stress markers in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
Thymosin beta4 protects mice from bleomycin-induced damage in the lung
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Pirfenidone attenuates myofibroblast differentiation during insufficient mitophagy
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Aerobic training inhibits bleomycin-induced pulmonary fibrosis in BALB/c mice
Source: International Congress 2014 – Animal models: asthma, COPD and beyond
Year: 2014
Severe lung inflammation is a feature of IPF
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities
Year: 2013
Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Ghrelin protects against bleomycin-induced pulmonary fibrosis in mice
Source: International Congress 2017 – Lung fibrosis: basic science
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept